1. Home
  2. IPHA vs LUCD Comparison

IPHA vs LUCD Comparison

Compare IPHA & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$2.15

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Logo Lucid Diagnostics Inc.

LUCD

Lucid Diagnostics Inc.

HOLD

Current Price

$0.94

Market Cap

192.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IPHA
LUCD
Founded
1999
2018
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.3M
192.9M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
IPHA
LUCD
Price
$2.15
$0.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$5.75
$4.13
AVG Volume (30 Days)
174.9K
807.4K
Earning Date
03-26-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.67
EPS
N/A
N/A
Revenue
N/A
$4,346,000.00
Revenue This Year
$180.36
$115.58
Revenue Next Year
N/A
$130.54
P/E Ratio
N/A
N/A
Revenue Growth
N/A
79.00
52 Week Low
$1.18
$0.86
52 Week High
$2.71
$1.63

Technical Indicators

Market Signals
Indicator
IPHA
LUCD
Relative Strength Index (RSI) 52.48 49.50
Support Level $1.67 $0.96
Resistance Level $2.66 $1.07
Average True Range (ATR) 0.08 0.05
MACD -0.02 0.00
Stochastic Oscillator 38.46 35.90

Price Performance

Historical Comparison
IPHA
LUCD

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

About LUCD Lucid Diagnostics Inc.

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Share on Social Networks: